Thursday, January 23, 2020 1:39:09 PM
His explanation of the delays that have occurred with the submission of the BLA was turned into a positive. The additional demands that the FDA made have provided a better platform for Leronlimab.
BLA submission is still on schedule for end of January. Could slip a week or two but they are all over the final details working around the clock.
His explanation of the MOA and impact on Macrophages was powerful. He explains in layman terms what separates Leronlimab from Maravirov and other CCR5 inhibitors.
Patients 3 and 4 have been injected - #3 was Jan. 2 and he expects first data on these patients as early as next week. He also expects patients 5,6,and 7 to be injected by end of next week. He is inquiring on a daily basis for clinical updates to keep SH’s in the loop. Goal is to get 50 patients injected as quickly as possible. They have filed for Basket trial to expedite enrollment.
They are in discussions with 18 companies for $40-$50M non dilutive financing. They expect non binding term sheets to begin hitting his desk next week.
Someone wanted to know about current $ in the bank. He was quite confident about the companies position with warrants being converted coupled with a much appreciated SP. He isn’t going to jump at any cash deals that take advantage of our current SP. I got the feeling Nader is very comfortable with the leverage that is starting to build with the BLA submission and mTNBC play.
NASH will have published data very soon and they feel there is a strong likelihood of a BP deal.
Number one I goal is to help the many patients lives that can be saved. Number two is SH’s ROI. He said we can’t reach goal number one without first achieving goal #2.
Things are ramping up on a daily basis in terms of possible PR’s. Once again why anyone in there right mind would sell this stock at this juncture is beyond me.
GLTAL’s
Recent CYDY News
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/06/2024 09:17:30 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/06/2024 09:16:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 09:09:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2024 02:30:20 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/01/2024 10:16:47 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/01/2024 10:15:34 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/22/2024 10:16:11 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/22/2024 05:15:08 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 02:00:24 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/12/2024 10:31:57 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/29/2024 10:22:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/29/2024 01:40:14 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/19/2024 10:15:35 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/16/2024 10:16:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:04:57 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:04:20 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:02:59 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:02:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:01:55 AM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM